Trinity Biotech's Deal Values Metabolomics Diagnostics With An Enterprise Value Of ~$1.3M With The Consideration Consisting Of Just Over 270,000 Trinity Biotech's ADS With The Balance Of Consideration Being In Cash And The Assumption Of Liabilities
Portfolio Pulse from Benzinga Newsdesk
Trinity Biotech has acquired Metabolomics Diagnostics, valuing it at $1.3M. The acquisition includes cash, liabilities, and over 270,000 Trinity Biotech ADS. The PrePsia test for preeclampsia will be commercialized in the U.S. by 2025.
September 24, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trinity Biotech's acquisition of Metabolomics Diagnostics for $1.3M includes cash, liabilities, and over 270,000 ADS. This strategic move enhances Trinity's diagnostic capabilities with the PrePsia test, set for U.S. commercialization in 2025.
The acquisition of Metabolomics Diagnostics provides Trinity Biotech with a new diagnostic platform and the PrePsia test, which could drive future growth. The U.S. commercialization plan for 2025 suggests a positive long-term impact on Trinity's market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100